The fund seeks capital appreciation in the long term by investing in companies across any size in the United States.
The investment process is driven by a value-oriented approach to identify undervalued companies that are lagging in market price or trading at a discount to their estimated intrinsic value not yet recognized by investors.
The research team relies on fundamental analysis to buy good businesses at attractive prices.
The research team also reviews a company’s free cash flow generation, balance sheet strength, the quality of their business franchise, and long-term fundamentals.
The portfolio holds between 60 and 80 stocks. The research process is driven by fundamental analysis of one stock at a time, and does not try to replicate a benchmark.
The fund has the flexibility to invest up to 25% of its net assets in non-U.S. companies, including in American Depositary Receipts, in both developed and emerging markets.
The fund seeks capital appreciation in the long term by investing in small-and mid-size companies in the United States.
The investment process starts with a list of companies in the benchmark index and the research team utilizes quantitative techniques and fundamental analysis to identify investment opportunities.
Next, the research team invests in companies that exhibit above-average earnings growth potential over the long term. Such companies may include, but not limited to, information technology, and health care companies.
The team favors companies which are market leaders in growth industries.
Also, the team considers companies with steady sales and earnings growth.
In addition to meeting with corporate management teams, the team reviews a company’s financial statements focusing on earnings, sales growth, valuation, and profitability.
Then the manager constructs a portfolio of stocks from a list of companies favored by the research team and allocates capital based on its conviction level.
The fund invests in a number of sectors and industries in the U.S.
In addition, the fund may invest up to 20% of its net assets in non-U.S. securities, including in ADRs, in both developed and emerging markets.
